Fintel reports that on November 18, 2024, Needham downgraded their outlook for Biogen (NasdaqGS:BIIB) from Buy to Hold.

“At Biogen Digital Health we have a full team dedicated to patient experience and user insights,” he said. “Their mission is to start from the need, improve the experience, and iterate.

Biogen Background Information (This description is provided by the company.) At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide ...

Biogen Background Information (This description is provided by the company.) At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide ...

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA ...

Biogen has added a preclinical-stage drug candidate for Parkinson's disease via a $722.5 million licensing agreement with Alectos Therapeutic, as it continues to rebuild a pipeline behind its side ...

Oct 30 (Reuters) - Biogen (BIIB.O), opens new tab raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of its multiple sclerosis drugs.

Investors with a lot of money to spend have taken a bearish stance on Biogen BIIB. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

Biogen Inc. (NASDAQ:BIIB) the central nervous system disease drug developer based in Cambridge Massachusetts, reported its Q3 earnings yesterday, Wednesday, October 30. First, let's look at some ...